Immunofan - characterization and significance as immunomodulator in malignant diseases

Abstract

Immunofan is a modern effective immunomodulator as a product of the newest tendency in world medicine - the molecular nanotechnology. The author and discoverer of the unique patent medicine is Prof. Dr. Vasilii Lebedev. The product is manifectured in three forms: sterile ampullae, spray doses and suppositories in Scientific-manufacture complex `Bionox` in Moscow. Pharmaceutical effect of Immunofan is manifested in three basic directions:

• Restoration the balance of the oxidation and restoration processes in the organism;
• Correct the immune system in cases, when the immune system is destroyed in appearance of malignant formation, disease respectively;
• Remove the possibility for multiple drug resistance (MDR), and by this way the effect of the treatment with other drugs is increased in patients with malignant disease.

For the first time in the world a new medicine is created that give the chance to be used to abolish the multiple drug resistance. In the treatment of malignant diseases it is concerned that during the period of chemotherapy should not be taken immunomodulators, because they increase cellular mitotic activity. Just the opposite is the idea that Immunofan should be taken exactly during the time of chemotherapy, because the multiple drug resistance is avoided, returning the cellular sensitiveness to therapeutic effect of chemotherapy. Overcoming multiple drug resistance, the most powerful effect of medicines is achieved in treatment. The effect of Immunofan is developed and keeps for 2-3 hours (rapid phase) and is continued to 4 months (moderate and prolonged phases). In patients with cancer two ways of therapy is recommended. First: by inclusion in general scheme of multipurpose treatment (chemotherapy and operation), and at that moment start the application of Iimmunofan just before chemotherapy or operation, and second followed by continuing of application the medicine during the whole therapeutic period. It is accepted that Immunofan is a patent medicine that has no analogue among immunomodulators manufactured to this moment in different countries in the world. In patients with cancer Immunofan is with proved effectiveness and is received permission and license for application in medicine. Immunofan is recommended not only for cancer prevention, but for appropriate therapeutic patent medicine with proved effectiveness in secondary and tertiary prevention of cancer. That gives the possibility for prolongation and improvement of life property of patients with cancer.